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Multiparametric magnetic resonance imaging (mpMRI) is 
the current state-of-the-art imaging modality in the assess-
ment of patients with suspected or confirmed prostate 
cancer (PC). In mpMRI morphological T2-weighted images 
(T2-WI) are supplemented with diffusion-weighted imag-
ing (DWI) and dynamic contrast-enhanced imaging (DCE). 
High-grade PC can be detected on mpMRI with high accu-
racy as it typically appears as a low signal intensity lesion 
on T2-WI (Figure 1), with restricted diffusion (Figure 2) 
and strong contrast enhancement. With the technical 
improvement of the available DWI sequences in recent 
years, the added value of performing DCE in all patients is 
currently being questioned.
To standardize the scanning protocol and the inter-
pretation of mpMRI, the European Society of Urogenital 
Radiology (ESUR) introduced the Prostate Imaging and 
Reporting and Database System (PI-RADS) in 2011, which 
was adopted by the American College of Radiology (ACR) 
in 2015 (PI-RADS version 2). The PI-RADS scoring system 
reflects the likelihood of the presence of a clinically signif-
icant PC on a 5-point scale. In 2019, some refinements and 
clarifications were made, which resulted in an updated 
version, PI-RADS v2.1.
In patients with elevated PSA, traditionally a systematic 
(i.e. 10–12 cores taken randomly throughout the pros-
tate) transrectal ultrasound (TRUS) guided prostate biopsy 
is performed to detect PC, but in up to 30% of cases the 
tumor or the most aggressive components of the tumor 
are missed. Recently published level A evidence and the 
2019 updated guidelines of the European Association of 
Urology have shown that it is advantageous to perform 
mpMRI of the prostate before a biopsy. When mpMRI is 
normal, the risk of a clinically significant tumor is low and 
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Figure 1: Axial T2-WI of the prostate in a 66-year-old man 
with PSA of 10 ng/ml. Far anteriorly and cranially on the 
left side in the transition zone of the prostate there is an 
ill-defined marked low-signal intensity area (white star) 
with irregular contour, suspicious for prostate cancer.
Figure 2: Axial ADC map of DWI in the same patient and 
at the same level as Figure 1. The lesion shows very low 
ADC value (white star) with corresponding very high 
signal intensity on the high-b-value images (not pre-
sented), which is suggestive of a high-grade prostate 
cancer. In the radiology report this lesion was scored 
PI-RADS 4, indicating that the likelihood of a clinically 
significant prostate cancer is high.
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the biopsy may be postponed, provided that the patient is 
closely clinically followed up. When a suspicious lesion is 
detected on mpMRI, a targeted biopsy can be performed. 
There are three methods to perform a MRI targeted 
biopsy: cognitive, US-MRI fusion and in-bore MRI-guided 
biopsy. With a cognitive approach, the clinician keeps the 
MRI images in mind when performing a random TRUS 
biopsy with some additional cores in the region where 
the suspicious lesion is about located. This method is 
most frequently used in clinical practice because it is fast 
and cheap. For large PC this method is sufficient, but for 
very small or anteriorly located lesions it is less accurate. 
With TRUS-MRI fusion, dedicated software is used to fuse 
the MRI images virtually with the live TRUS images. A 
random biopsy is performed with some additional cores 
to the region where the suspicious lesion is highlighted 
by the software. An in-bore MRI guided prostate biopsy 
(Figure 3) is performed while the patient is in the MRI 
scanner and the position of the biopsy needle is followed 
with repetitive scans. This is the most accurate method to 
take a biopsy of target lesions that are very small or are at 
a difficult location in the prostate.
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Figure 3: Axial T2-WI of in-bore MRI guided transrectal 
prostate biopsy in the same patient and at the same level 
as Figures 1 and 2. The patient initially underwent a sys-
tematic transrectal ultrasound guided prostate biopsy 
but the pathology result showed no malignancy. Because 
of the persistently rising PSA and the difficult location of 
the suspicious lesion, an in-bore MRI guided transrectal 
prostate biopsy was performed. The position of the tran-
srectal needle guide (thick line) and the tru-cut biopsy 
needle (fine line) are demonstrated on the T2-WI and 
confirm that the suspicious lesion is sampled correctly. 
Two biopsy cores were taken, and the pathology result 
revealed Gleason 4 + 4 prostate cancer in both of them.
